Kymera Secures $1.6B Runway, Posts 35% FeNO Drop, Initiates IRF5 Dosing
Kymera reported Phase Ib atopic dermatitis data showing 25–35% FeNO reduction (55% in asthma subgroup) and robust STAT6 degradation supporting Phase IIb trials. The IRF5 degrader program has begun dosing with healthy‐volunteer data due in H2 2026, and $1.6B in cash funds operations into 2029.
1. Phase Ib AD Study Results
The Phase Ib open‐label atopic dermatitis trial evaluated 100 mg and 200 mg doses of KT-621 in 22 patients with moderate-to-severe AD. The study demonstrated robust STAT6 degradation in blood and skin lesions, supported by 25–35% FeNO reductions in AD patients and a 55% decrease in the asthma subgroup, reinforcing dose selection for Phase IIb studies.
2. IRF5 Degrader Program Progress
Kymera has initiated dosing in a healthy-volunteer study of its IRF5 degrader, reporting safety and tolerability profiles comparable to placebo alongside clean 6- and 9-month chronic toxicology data at high doses. Healthy-volunteer results are expected in H2 2026, with initial proof-of-concept likely in lupus and key partner‐program milestones on track.
3. Financial Runway and Strategic Pivot
The company holds $1.6 billion in cash, extending its operational runway into 2029 and underwriting six clinical IMiD degrader programs. Over the past 12–18 months, Kymera has transitioned from an oncology focus to immunology and inflammation, targeting well-established biology and large market opportunities for protein degradation therapies.